Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

adriamycin/vähk

Link salvestatakse lõikelauale
Leht 1 alates 4096 tulemused
An anticancer drug adriamycin (ADR) was incorporated into polymeric micelles forming from poly(ethylene glycol)-poly(aspartic acid) block copolymer by chemical conjugation and physical entrapment. Structural stability of the polymeric micelles was found to be dependent on both the contents of

Metabolomic approach to evaluating adriamycin pharmacodynamics and resistance in breast cancer cells.

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Continuous exposure of breast cancer cells to adriamycin induces high expression of P-gp and multiple drug resistance. However, the biochemical process and the underlying mechanisms for the gradually induced resistance are not clear. To explore the underlying mechanism and evaluate the anti-tumor

Astragalus Polysaccharide Promotes Adriamycin-Induced Apoptosis in Gastric Cancer Cells.

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse

Purpose
Astragalus polysaccharide (APS), a common Chinese herbal compound extracted from Astragalus membranaceus, has been proposed to increase the tumour response of and stabilize chemotherapy drugs while reducing their toxicity. Here, we examined the effects of
The current treatment of breast carcinomas recognizes the importance of combination therapy in order to increase efficacy and decrease side effects of conventional chemotherapy. Inositol hexaphosphate (IP6), a naturally occurring polyphosphorylated carbohydrate, has shown a significant anti-cancer

Blockade of GLUT1 by WZB117 resensitizes breast cancer cells to adriamycin.

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The tolerance to adriamycin of cancer as a common and stubborn obstacle occurred during curing breast cancer patients needs to be overcome. In the present study, we explored whether inhibiting the glucose transporter 1 (GLUT1) could restore the activity of adriamycin in breast cancer cell line MCF-7

Targeted cancer therapy with a 2-deoxyglucose-based adriamycin complex.

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Adriamycin (ADM) has been effective against many types of solid tumors in clinical applications. However, its use is limited because of systemic toxicities, primarily cardiotoxicity, and multidrug resistance. In this study, a new active receptor-mediated complex, ADM conjugated with
Seven consecutive cases of primary hypervascular bone tumor, encountered between January 1991 and September 1992, were treated with intraarterial cisplatinum and intravenous adriamycin infusion. There were four osteosarcomas, one malignant fibrous histiocytoma, one chondrosarcoma and one case of

A pharmacological rationale for neoadjuvant chemotherapy with adriamycin in locally advanced breast cancer.

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Some locally advanced neoplastic diseases (i.e. head and neck cancer, breast cancer and osteogenic sarcoma), benefit from neoadjuvant chemotherapy with a resultant enhanced operability and a longer disease-free survival. The pharmacological study of the tissue distribution of adriamycin in patients

Adriamycin, CCNU, and 5-fluorouracil in patients with advanced gastrointestinal cancer.

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Forty-one patients with measurable advanced gastrointestinal malignancy were treated with a combination of Adriamycin (doxorubicin), 5-FU (5-fluorouracil), and CCNU (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea). The response to therapy was evaluated every eight weeks. In addition to standard

Regional intra-arterial infusion of adriamycin in the treatment of cancer.

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Forty patients with otherwise untreatable advanced carcinomas received arterial infusions of adriamycin. Significant responses were seen in five of nine tumors of the bladder, two of five hypernephromas, two of two islet cell tumors, three of five sarcomas and one of two metastatic tumors of the

[Adriamycin, cisplatin and etoposide combination chemotherapy in non-small cell lung cancer].

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Nineteen patients with non-small cell lung cancer (eight patients with adenocarcinoma, nine patients with squamous cell carcinoma, one patient with large cell carcinoma and one patient with sarcoma) who had not received previous chemotherapy were treated with a combination of adriamycin (30 mg/m2,

[New management of brain neoplasms. 2. Local injection of adriamycin].

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
This is the second paper on a trial treatment of malignant brain tumors by postoperative intracavity chemotherapy. In 34 patients with malignant brain tumors in cerebral hemispheres, 0.5 mg adriamycin (ADM) was injected through an Ommaya's device into the tumor-bed every other day after subtotal

High-dose cyclophosphamide, adriamycin, and vincristine (HD-CAV) in children with recurrent solid tumor.

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
A dose-intensive regimen of cyclophosphamide (140 mg/kg over 2 days), doxorubicin (Adriamycin, 75 mg/m2 over 3 days), and vincristine (1 mg/m2 on days 1, 2, and 3 and 1.5 mg/m2 on day 9) was tested in 18 children and adolescents with poor-prognosis recurrent or refractory solid tumors. Nine were
The effect of preoperative intra-arterial infusion of mitomycin C, 5-fluorouracil (5-FU) and adriamycin (ADM) were studied in seven patients with locally advanced breast cancer, including five inflammatory carcinomas, and a patient with stromal sarcoma of the breast. Reducing rate of the primary
Regression analysis has been applied to compare the tumor response following the administration of free and microsphere-loaded adriamycin to the rats. A nonmetastasizing sarcoma was induced in male A.S. inbred rats. When the sarcoma was in its fourth passage and 12 days old, four groups of animals
Liitu meie
facebooki lehega

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus

  • Töötab 55 keeles
  • Taimsed ravimid, mida toetab teadus
  • Maitsetaimede äratundmine pildi järgi
  • Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
  • Lugege oma otsinguga seotud teaduspublikatsioone
  • Otsige ravimtaimi nende mõju järgi
  • Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega

Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel

Google Play badgeApp Store badge